Younger age as a prognostic indicator in breast cancer: A cohort study

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Kheirelseid, Elrasheid A H ^a   Boggs, Jennifer M E ^a   Curran, Catherine ^a   Glynn, Ronan W ^a   Dooley, Cara ^a   Sweeney, Karl J ^a   Kerin, Michael J ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INCIDENCE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE; GENE OVEREXPRESSION; HER2 GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS; TUMOR VOLUME; AGE; BREAST TUMOR; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; TUMOR RECURRENCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 80052029797     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-383     Document Type: Article

References (50)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. Ca-a Cancer Journal for Clinicians 2005, 55(2):74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Swanson GM, Lin CS. Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. J Natl Cancer Inst Monogr 1994, 16:69-77.
3. Brinton LA, Sherman ME, Carreon JD, Anderson WF. Recent Trends in Breast Cancer Among Younger Women in the United States. Journal of the National Cancer Institute 2008, 100(22):1643-1648. 10.1093/jnci/djn344, 2720764, 19001605.
4. Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 1996, 77(1):97-103. 10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO;2-3, 8630946.
5. Sidoni A, Cavaliere A, Bellezza G, Scheibel M, Bucciarelli E. Breast cancer in young women: clinicopathological features and biological specificity. Breast 2003, 12(4):247-250. 10.1016/S0960-9776(03)00095-X, 14659308.
6. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated Breast Cancer Mortality in Women Younger than Age 40 Years Compared with Older Women Is Attributed to Poorer Survival in Early-Stage Disease. Journal of the American College of Surgeons 2009, 208(3):341-347. 10.1016/j.jamcollsurg.2008.12.001, 19317994.
7. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment. PLoS One 2009, 4(11):A38-A46.
8. Gajdos C, Tartter PI, Bleiweiss IJ, Bodian C, Brower ST. Stage 0 to stage III breast cancer in young women. Journal of the American College of Surgeons 2000, 190(5):523-529. 10.1016/S1072-7515(00)00257-X, 10801018.
9. Maggard MA, O'Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY. Do young breast cancer patients have worse outcomes?. Journal of Surgical Research 2003, 113(1):109-113. 10.1016/S0022-4804(03)00179-3, 12943818.
10. Kimura M, Yanagita Y, Fujisawa T, Koida T. Study of time-course changes in annual recurrence rates for breast cancer: Data analysis of 2,209 patients for 10 years post-surgery. Breast Cancer Research and Treatment 2007, 106(3):407-411. 10.1007/s10549-007-9510-2, 17268809.
11. Daniel SR, Armstrong K, Silber JH, Rosenbaum PR. An Algorithm for Optimal Tapered Matching, With Application to Disparities in Survival. Journal of Computational and Graphical Statistics 2008, 17(4):914-924.
12. R Development Core Team R: A Language and Environment for Statistical Computing. 2008, Vienna, Austria: R Foundation for Statistical computing, R Development Core Team.
13. Bharat A, Aft RL, Gao F, Margenthaler JA. Patient and Tumor Characteristics Associated With Increased Mortality in Young Women (< = 40 Years) With Breast Cancer. Journal of Surgical Oncology 2009, 100(3):248-251. 10.1002/jso.21268, 19330813.
14. Foo CS, Su D, Chong CK, Chng HC, Tay KH, Low SC, Tan SM. Breast cancer in young Asian women: Study on survival. Anz Journal of Surgery 2005, 75(7):566-572. 10.1111/j.1445-2197.2005.03431.x, 15972049.
15. Bonnier P, Romain S, Charpin C, Lejeune C, Tubiana N, Martin PM, Piana L. Age as a Prognostic Factor in Breast-Cancer - Relationship to Pathological and Biologic Features. International Journal of Cancer 1995, 62(2):138-144.
16. Xiong QH, Valero V, Kau V, Kau SW, Taylor S, Smith TL, Smith TL, Buzdar AU, Hortobagyi GN, Theriault RL. Female patients with breast carcinoma age 30 years and younger have a poor prognosis - The M. D. Anderson Cancer Center Experience. Cancer 2001, 92(10):2523-2528. 10.1002/1097-0142(20011115)92:10<2523::AID-CNCR1603>3.0.CO;2-6, 11745185.
17. Kollias J, Elston CW, Ellis IO, Robertson JFR, Blamey RW. Early-onset breast cancer - Histopathological and prognostic considerations. British Journal of Cancer 1997, 75(9):1318-1323. 10.1038/bjc.1997.223, 2228226, 9155052.
18. Yildirim E, Dalgic T, Berberoglu U. Prognostic significance of young age in breast cancer. Journal of Surgical Oncology 2000, 74(4):267-272. 10.1002/1096-9098(200008)74:4<267::AID-JSO5>3.0.CO;2-N, 10962458.
19. McAree B, O'Donnell ME, Spence A, Lioe TF, McManus DT, Spence RA. Breast cancer in women under 40 years of age: a series of 57 cases from Northern Ireland. Breast 2010, 19(2):97-104. 10.1016/j.breast.2009.12.002, 20060718.
20. Leung GM, Thach TQ, Lam TH, Hedley AJ, Fielding R, Yip PSF, Lau EMC, Wong CM. Trends in breast cancer incidence in Hong Kong between 1973 and 1999: an age-period-cohort analysis. British Journal of Cancer 2002, 87(9):982-988. 10.1038/sj.bjc.6600583, 2364319, 12434289.
21. Feldman AL, Welch JP. Long-term outcome in women less than 30 years of age with breast cancer. Journal of Surgical Oncology 1998, 68(3):193-198. 10.1002/(SICI)1096-9098(199807)68:3<193::AID-JSO12>3.0.CO;2-2, 9701214.
22. Livi L, Meattini I, Saieva C, Borghesi S, Scotti V, Petrucci A, Rampini A, Marrazzo L, Di Cataldo V, Bianchi S, et al. The impact of young age on breast cancer outcome. Eur J Surg Oncol 2010,
23. Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Oei SB, Peterse HL, Pierart M, Poortmans PM, et al. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?. European Journal of Cancer 2003, 39(7):932-944. 10.1016/S0959-8049(03)00123-0, 12706362.
24. Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, Luini A, Veronesi P, Intra M, Orecchia R, et al. Very young women (< 35 years) with operable breast cancer: features of disease at presentation. Annals of Oncology 2002, 13(2):273-279. 10.1093/annonc/mdf039, 12401701.
25. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. Journal of Clinical Oncology 2008, 26(15):2568-2581. 10.1200/JCO.2007.13.1748, 18487574.
26. Kwong A, Cheung P, Chan S, Lau S. Breast Cancer in Chinese Women Younger than Age 40: Are They Different from Their Older Counterparts?. World Journal of Surgery 2008, 32(12):2554-2561. 10.1007/s00268-008-9589-6, 18408960.
27. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buccholz TA, et al. Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. Journal of Clinical Oncology 2005, 23(1):41-48.
28. van Nes JG, van de Velde CJ. The preferred treatment for young women with breast cancer--mastectomy versus breast conservation. Braest 2006, 15(Suppl 2):S3-10.
29. Zhou P, Gautam S, Recht A. Factors affecting outcome for young women with early stage invasive breast cancer treated with breast-conserving therapy. Breast Cancer Research and Treatment 2007, 101(1):51-57. 10.1007/s10549-006-9268-y, 16821084.
30. EBCTCG Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000, 355(9217):1757-1770. EBCTCG.
31. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366(9503):2087-2106.
32. Masinghe SP, Faluyi OO, Kerr GR, Kunkler IH. Breast radiotherapy for occult breast cancer with axillary nodal metastases--does it reduce the local recurrence rate and increase overall survival?. Clinical Oncology 2011, 23(2):95-100. 10.1016/j.clon.2010.10.001, 21115330.
33. Yang PS, Chen CM, Liu MC, Jian JM, Horng CF, Liu MJ, Yu BL, Lee MY, Chi CW. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status. Int J Radiat Oncol Biol Phys 2009, 77(2):516-522.
34. Kunkler IH, Williams LJ, King CC, Jack W. Breast radiotherapy: considerations in older patients. Clinical Oncology 2009, 21(2):111-117. 10.1016/j.clon.2008.11.012, 19121926.
35. Kyndi M, Overgaard M, Nielsen HM, Sørensen FB, Knudsen H, Overgaard J. High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. Radiother Oncol 2009, 90(1):74-79. 10.1016/j.radonc.2008.04.014, 18471914.
36. Overgaard M. Overview of randomized trials in high risk breast cancer patients treated with adjuvant systemic therapy with or without postmastectomy irradiation. Semin Radiat Oncol 1999, 9(3):292-299. 10.1016/S1053-4296(99)80022-8, 10378969.
37. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007, 82(3):247-253. 10.1016/j.radonc.2007.02.001, 17306393.
38. Whelan T, Levine M. More evidence that locoregional radiation therapy improves survival: what should we do?. J Natl Cancer Inst Monogr 2005, 97(2):82-84.
39. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L, Gelmon K, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst Monogr 2005, 97(2):116-126.
40. Menard S, Casalini P, Cascinelli N, Balsari A. Breast carcinoma in young patients. Lancet 2000, 356(9235):1113-1113.
41. Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Nomura Y, Sakai K, Sugimachi K, Tominaga T, Uchino J, et al. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998, 352(9132):930-942.
42. EBCTCG Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717. EBCTCG.
43. Andersson M, Kamby C, Jensen MB, Mouridsen H, Ejlertsen B, Dombernowsky P, Rose C, Cold S, Overgaard M, Andersen J, et al. Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-Operative Group DBCG 82B trial. European Journal of Cancer 1999, 35(12):1659-1666. 10.1016/S0959-8049(99)00141-0, 10674010.
44. Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. Journal of Clinical Oncology 2006, 24(9):1332-1341.
45. Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, et al. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: A randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group. European Journal of Cancer 2007, 43(2):331-340. 10.1016/j.ejca.2006.10.009, 17134892.
46. Margolin KA, Liu PY, Unger JM, Fletcher WS, Flaherty LE, Urba WJ, Hersh EM, Hutchins LE, Sosman JA, Smith JW, et al. Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial. Journal of Cancer Research and Clinical Oncology 1999, 125(5):292-296. 10.1007/s004320050276, 10359134.
47. Anderson BO, Senie RT, Vetto JT, Wong GY, McCormick B, Borgen PI. Improved Survival in Young-Women with Breast-Cancer. Annals of Surgical Oncology 1995, 2(5):407-415. 10.1007/BF02306373, 7496835.
48. Pritchard KI. Adjuvant therapy of the very young woman. Breast 2007, 16:S136-S146.
49. Abe O, Abe R, Asaishi K, Enomoto K, Hattori T, Ino Y, Kikuchi K, Koyama H, Sawa K, Uchino J, et al. Systemic Treatment of Early Breast-Cancer by Hormonal, Cytotoxic, or Immune Therapy - 133 Randomized Trials Involving 31000 Recurrences and 24000 Deaths among 75000 Women .2. Lancet 1992, 339(8785):71-85.
50. Chia S, Bryce C, Gelmon K. The 2000 EBCTCG overview: a widening gap. Lancet 2005, 365(9472):1665-1666. 10.1016/S0140-6736(05)66524-5, 15894082.